WASHINGTON: The U.S. House of Representatives on Monday brushed aside a major obstacle to the full establishment of Coltsville National Park by approving legislation that changes the site of the park’s headquarters.
Coltsville was established by legislation Congress approved in December of 2014. That legislation required that the National Park Service be given 10,000 square feet of space in the Colt complex’s blue-domed East Armory in Hartford.
But the park service and the company developing some of Sam Colt’s former properties, including the East Armory, decided two one-story brownstones next to the armory would better serve as offices for park administration and visitor services. The two buildings were constructed in 1855 and are all that remains of Sam Colt’s original factories.
By MItchell Young
HARTFORD: The date has been set and registration is open for The Connecticut Governor’s Conference on Tourism [registration link] on May 4th at the Connecticut Convention Center.
The confab comes at a time that Connecticut’s largest tourism draws, the Foxwoods and the Mohegan Casinos are bracing for significant competition from new casinos, in neighboring Massachusetts and New York.
The Nutmeg tourism industry is said to employ more than 60,000 people, nearly a third at the two Casinos and their immediate vicinity. The Connecticut Department of Economic and Community Development [DECD] says, that overall tourism employment grew 13.6% in the past ten years and the Department of Tourism says that more than 1.6 million people visited Connecticut in 2015.
Study Finds Connecticut A Fine Place To Do Business
Economist Klepper-Smith: “Some positives that are undeniable.”
DECD Commissioner Smith: We’re high value in many ways.”
CBIA’s Brennan: “We have amazing assets here.”
There has been no shortage of criticism of Connecticut’s business climate in recent years as the state recovers slowly from the Great Recession.
But a new study issued in December by the Council on State Taxation concludes Connecticut actually is tied for the most favorable business climate — if one considers not just the cost of doing business, but the potential for earning big profits here.
And while the report has its supporters and critics, it shows the task of evaluating Connecticut’s readiness to do business is not simple.
Who’s Your Data?
HARTFORD: New search capabilities of the state’s business formation database have been made available through a partnership with the Connecticut Secretary of State’s office and the Connecticut Data Collaborative. Searching is more flexible than the secretary’s official CONCORD System. The new database doesn’t include all the information found on Concord, such as shareholder information but users can search by town or date, and type of formation, [ LLC, Corp., Foreign etc.], sole proprietorships are not currently in the database, in the Concord system the business name or ID is required.
A quick search showed more than 424,000 active and inactive business records and 824 new business formations in the city of New Haven in the past year, 38 used New Haven in their name itself. The website can be reached at searchctbusiness.ctdata.org
HARTFORD: Connecticut has joined a $19.5-million multi-state settlement with drug maker Bristol-Myers Squibb [NYSE: BMY] based in New York to resolve allegations that the company improperly marketed the antipsychotic drug Abilify.
A joint release by Attorney General George Jepsen and state Department of Consumer Protection (DCP) Commissioner Jonathan A. Harris announced the Connecticut’s share of the settlement funds is $310,133.
Of those settlement funds, $15,000 will be deposited in DCP’s Consumer Protection Fund and $15,000 will be deposited in the attorney general’s Consumer Protection Fund; both funds are used by the respective agencies to support investigations, training and consumer outreach efforts. The remaining settlement funds will be deposited in the state’s general fund.
Abilify is the brand name for the prescription drug aripiprazole, which was originally approved by the U.S. Food and Drug Administration (FDA) in 2002 for the treatment of schizophrenia in adults.